Danh Tran-Thanh
Overview
Explore the profile of Danh Tran-Thanh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robichaud S, Tran-Thanh D, Zhang Z, Durocher F, Rahimi K
Int J Surg Pathol
. 2025 Feb;
:10668969251314125.
PMID: 39962834
Ectopic breast is found to occur most commonly in the axilla, but also less commonly on the vulva and on sites outside the "milk line" like the face, neck and...
2.
Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, et al.
Cancer Treat Res Commun
. 2023 Oct;
37:100767.
PMID: 37832364
Background: PD-L1 expression is used to predict NSCLC response to ICIs, but its performance is suboptimal. The impact of KRAS mutations in these patients is unclear. Studies evaluating co-mutations in...
3.
Stockley T, Lo B, Box A, Gomez Corredor A, DeCoteau J, Desmeules P, et al.
Curr Oncol
. 2023 May;
30(4):3989-3997.
PMID: 37185415
The detection of gene fusions by RNA-based next-generation sequencing (NGS) is an emerging method in clinical genetic laboratories for oncology biomarker testing to direct targeted therapy selections. A recent Canadian...
4.
Beniey M, Hubert A, Haque T, Cotte A, Bechir N, Zhang X, et al.
Br J Cancer
. 2023 Mar;
128(10):1964-1975.
PMID: 36941406
Background: Patients with triple-negative breast cancer (TNBC) develop early recurrence. While PARP inhibitors (PARPi) have demonstrated potential in BRCA1/2-mutant (BRCA) TNBC, durable responses will likely be achieved if PARPi are...
5.
Stockley T, Lo B, Box A, Gomez Corredor A, DeCoteau J, Desmeules P, et al.
J Mol Diagn
. 2022 Dec;
25(3):168-174.
PMID: 36586421
The Canadian NTRK (CANTRK) study is an interlaboratory comparison ring study to optimize testing for neurotrophic receptor tyrosine kinase (NTRK) fusions in Canadian laboratories. Sixteen diagnostic laboratories used next-generation sequencing...
6.
Selvarajah S, Plante S, Speevak M, Vaags A, Hamelinck D, Butcher M, et al.
JTO Clin Res Rep
. 2021 Sep;
2(8):100212.
PMID: 34590051
Introduction: Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the T790M resistance mutation in patients with advanced NSCLC with resistance to EGFR inhibitors. To facilitate...
7.
Cheung C, Smith A, Albadine R, Bigras G, Bojarski A, Couture C, et al.
Lung Cancer
. 2021 Sep;
160:127-135.
PMID: 34509095
Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1) gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) crizotinib. Current best practice guidelines recommend that...
8.
Roy S, Wong J, Le Page C, Tran-Thanh D, Barkati M, Pina A, et al.
Histopathology
. 2021 Jul;
79(6):975-988.
PMID: 34265101
Aims: We aimed to characterise a large cohort of non-invasive, human papillomavirus (HPV) and p53-independent verruciform lesions, such as 'vulvar acanthosis with altered differentiation' (VAAD), 'differentiated exophytic vulvar intra-epithelial lesion'...
9.
Blanc-Durand F, Florescu M, Tehfe M, Routy B, Alameddine R, Tran-Thanh D, et al.
Curr Oncol
. 2021 Mar;
28(2):1045-1055.
PMID: 33652831
Background: Epidermal growth factor receptor (EGFR) is the most common oncogenic mutation in lung adenocarcinoma and tyrosine kinase inhibitors (TKIs) have been considered standard treatment for more than a decade....
10.
Gauvin C, Krishnan V, Kaci I, Tran-Thanh D, Bedard K, Albadine R, et al.
Curr Oncol
. 2021 Jan;
28(1):593-605.
PMID: 33498159
Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint...